FDA approves AstraZeneca’s Ultomiris for NMOSD treatment
Betsy Goodfellow | March 25, 2024 | News story | Medical Communications | AstraZeneca, FDA, Neurology, Ultomiris, neuromyelitis optica spectrum disorder
AstraZeneca has announced that the US Food and Drug Administration (FDA) has approved Ultomiris (ravulizumab-cwvs) as the first and only long-acting C5 complement inhibitor for the treatment of adult patients with anti-aquaporin-4 (AQP4) antibody-positive (Ab+) neuromyelitis optica spectrum disorder (NMOSD).
This approval follows positive results from the phase 3 CHAMPION-NMOSD trial, which were published in the Annals of Neurology. In this trial, the drug met its primary endpoint of time to first on-trial relapse, which was confirmed by an independent adjudication committee. No relapses were reported among patients on Ultomiris with a median treatment duration of 73 weeks.
The trial demonstrated a consistent safety and tolerability profile, with no new safety signals being observed, however the most common adverse events were COVID-19, headache, back pain, arthralgia and urinary tract infection.
Marc Dunoyer, chief executive officer of Alexion, AstraZeneca’s rare disease division, commented: “Alexion has been at the forefront of innovation in NMOSD, striving to offer patients a future without fear of life-altering or even fatal relapses. Building on the established efficacy of C5 inhibition for people living with AQP4 Ab+ NMOSD, we are proud to deliver a transformative, long-acting treatment option that has the potential to eliminate relapses with a convenient dosing schedule every eight weeks. We are grateful to the NMOSD community for their ongoing collaboration and input, which enables us to advance science for rare diseases.”
Betsy Goodfellow
Related Content
MRM Health’s ulcerative colitis treatment receives FDA Investigational New Drug clearance
Microbial Resource Management (MRM) Health has announced that its lead programme, MH002, has received Investigational …
Complement Therapeutics’ geographic atrophy treatment receives FDA Fast Track designation
Complement Therapeutics has announced that CTx001, its gene therapy treatment for geographic atrophy (GA) secondary …
Johnson & Johnson submits robotic surgical system for De Novo classification
Johnson & Johnson has announced the submission of its Ottava Robotic Surgical System for De …
